{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "gpuType": "T4",
      "authorship_tag": "ABX9TyOKxf2cmjj8KJ+8DAy8Rxkj"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU"
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "dxqrpxxw2lGL",
        "outputId": "c42e628f-74a3-4d8f-ab32-a86da98cae32"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[?25l     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.0/86.0 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K     \u001b[91m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m\u001b[90m╺\u001b[0m\u001b[90m━\u001b[0m \u001b[32m81.9/86.0 kB\u001b[0m \u001b[31m2.8 MB/s\u001b[0m eta \u001b[36m0:00:01\u001b[0m\r\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m86.0/86.0 kB\u001b[0m \u001b[31m2.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h  Preparing metadata (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m21.3/21.3 MB\u001b[0m \u001b[31m61.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h  Building wheel for sentence-transformers (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "Collecting llama-index==0.9.29\n",
            "  Downloading llama_index-0.9.29-py3-none-any.whl (15.8 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m15.8/15.8 MB\u001b[0m \u001b[31m8.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: SQLAlchemy[asyncio]>=1.4.49 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (2.0.31)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.6 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (3.9.5)\n",
            "Requirement already satisfied: beautifulsoup4<5.0.0,>=4.12.2 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (4.12.3)\n",
            "Collecting dataclasses-json (from llama-index==0.9.29)\n",
            "  Downloading dataclasses_json-0.6.7-py3-none-any.whl (28 kB)\n",
            "Collecting deprecated>=1.2.9.3 (from llama-index==0.9.29)\n",
            "  Downloading Deprecated-1.2.14-py2.py3-none-any.whl (9.6 kB)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (2023.6.0)\n",
            "Collecting httpx (from llama-index==0.9.29)\n",
            "  Downloading httpx-0.27.0-py3-none-any.whl (75 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m75.6/75.6 kB\u001b[0m \u001b[31m10.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: nest-asyncio<2.0.0,>=1.5.8 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (1.6.0)\n",
            "Requirement already satisfied: networkx>=3.0 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (3.3)\n",
            "Requirement already satisfied: nltk<4.0.0,>=3.8.1 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (3.8.1)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (1.25.2)\n",
            "Collecting openai>=1.1.0 (from llama-index==0.9.29)\n",
            "  Downloading openai-1.35.7-py3-none-any.whl (327 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m327.5/327.5 kB\u001b[0m \u001b[31m33.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: pandas in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (2.0.3)\n",
            "Requirement already satisfied: requests>=2.31.0 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (2.31.0)\n",
            "Requirement already satisfied: tenacity<9.0.0,>=8.2.0 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (8.4.1)\n",
            "Collecting tiktoken>=0.3.3 (from llama-index==0.9.29)\n",
            "  Downloading tiktoken-0.7.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (1.1 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m1.1/1.1 MB\u001b[0m \u001b[31m38.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: typing-extensions>=4.5.0 in /usr/local/lib/python3.10/dist-packages (from llama-index==0.9.29) (4.12.2)\n",
            "Collecting typing-inspect>=0.8.0 (from llama-index==0.9.29)\n",
            "  Downloading typing_inspect-0.9.0-py3-none-any.whl (8.8 kB)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index==0.9.29) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index==0.9.29) (23.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index==0.9.29) (1.4.1)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index==0.9.29) (6.0.5)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index==0.9.29) (1.9.4)\n",
            "Requirement already satisfied: async-timeout<5.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index==0.9.29) (4.0.3)\n",
            "Requirement already satisfied: soupsieve>1.2 in /usr/local/lib/python3.10/dist-packages (from beautifulsoup4<5.0.0,>=4.12.2->llama-index==0.9.29) (2.5)\n",
            "Requirement already satisfied: wrapt<2,>=1.10 in /usr/local/lib/python3.10/dist-packages (from deprecated>=1.2.9.3->llama-index==0.9.29) (1.14.1)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from nltk<4.0.0,>=3.8.1->llama-index==0.9.29) (8.1.7)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.10/dist-packages (from nltk<4.0.0,>=3.8.1->llama-index==0.9.29) (1.4.2)\n",
            "Requirement already satisfied: regex>=2021.8.3 in /usr/local/lib/python3.10/dist-packages (from nltk<4.0.0,>=3.8.1->llama-index==0.9.29) (2024.5.15)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from nltk<4.0.0,>=3.8.1->llama-index==0.9.29) (4.66.4)\n",
            "Requirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.10/dist-packages (from openai>=1.1.0->llama-index==0.9.29) (3.7.1)\n",
            "Requirement already satisfied: distro<2,>=1.7.0 in /usr/lib/python3/dist-packages (from openai>=1.1.0->llama-index==0.9.29) (1.7.0)\n",
            "Requirement already satisfied: pydantic<3,>=1.9.0 in /usr/local/lib/python3.10/dist-packages (from openai>=1.1.0->llama-index==0.9.29) (2.7.4)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from openai>=1.1.0->llama-index==0.9.29) (1.3.1)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.10/dist-packages (from httpx->llama-index==0.9.29) (2024.6.2)\n",
            "Collecting httpcore==1.* (from httpx->llama-index==0.9.29)\n",
            "  Downloading httpcore-1.0.5-py3-none-any.whl (77 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m77.9/77.9 kB\u001b[0m \u001b[31m8.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: idna in /usr/local/lib/python3.10/dist-packages (from httpx->llama-index==0.9.29) (3.7)\n",
            "Collecting h11<0.15,>=0.13 (from httpcore==1.*->httpx->llama-index==0.9.29)\n",
            "  Downloading h11-0.14.0-py3-none-any.whl (58 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m58.3/58.3 kB\u001b[0m \u001b[31m7.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests>=2.31.0->llama-index==0.9.29) (3.3.2)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.31.0->llama-index==0.9.29) (2.0.7)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy[asyncio]>=1.4.49->llama-index==0.9.29) (3.0.3)\n",
            "Collecting mypy-extensions>=0.3.0 (from typing-inspect>=0.8.0->llama-index==0.9.29)\n",
            "  Downloading mypy_extensions-1.0.0-py3-none-any.whl (4.7 kB)\n",
            "Collecting marshmallow<4.0.0,>=3.18.0 (from dataclasses-json->llama-index==0.9.29)\n",
            "  Downloading marshmallow-3.21.3-py3-none-any.whl (49 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m49.2/49.2 kB\u001b[0m \u001b[31m6.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas->llama-index==0.9.29) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas->llama-index==0.9.29) (2023.4)\n",
            "Requirement already satisfied: tzdata>=2022.1 in /usr/local/lib/python3.10/dist-packages (from pandas->llama-index==0.9.29) (2024.1)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai>=1.1.0->llama-index==0.9.29) (1.2.1)\n",
            "Requirement already satisfied: packaging>=17.0 in /usr/local/lib/python3.10/dist-packages (from marshmallow<4.0.0,>=3.18.0->dataclasses-json->llama-index==0.9.29) (24.1)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai>=1.1.0->llama-index==0.9.29) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.18.4 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai>=1.1.0->llama-index==0.9.29) (2.18.4)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas->llama-index==0.9.29) (1.16.0)\n",
            "Installing collected packages: mypy-extensions, marshmallow, h11, deprecated, typing-inspect, tiktoken, httpcore, httpx, dataclasses-json, openai, llama-index\n",
            "Successfully installed dataclasses-json-0.6.7 deprecated-1.2.14 h11-0.14.0 httpcore-1.0.5 httpx-0.27.0 llama-index-0.9.29 marshmallow-3.21.3 mypy-extensions-1.0.0 openai-1.35.7 tiktoken-0.7.0 typing-inspect-0.9.0\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m60.0/60.0 kB\u001b[0m \u001b[31m1.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h"
          ]
        }
      ],
      "source": [
        "#visualization tool for displaying long load/processing times\n",
        "!pip install tqdm --quiet\n",
        "#data processing\n",
        "!pip install pandas --quiet\n",
        "#workhorse for converting text into embeddings/vectors\n",
        "!pip install sentence-transformers==2.2.2 --quiet\n",
        "#data framework for LLM applications\n",
        "!pip install llama-index==0.9.29\n",
        "#logging output\n",
        "!pip install loguru==0.7.0 --quiet\n",
        "#convenient pretty printing library\n",
        "!pip install rich --quiet\n",
        "#openai Tokenizer library\n",
        "!pip install tiktoken --quiet"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!curl -o Data_Med.json https://raw.githubusercontent.com/paramjeetn/Doctor_Copilot_V1/main/Data/Data_Med.JSON\n"
      ],
      "metadata": {
        "id": "TVNiZqzzJu_r",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "1f92b5d7-b247-447b-b709-6071b6c23044"
      },
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n",
            "                                 Dload  Upload   Total   Spent    Left  Speed\n",
            "100  101k  100  101k    0     0   162k      0 --:--:-- --:--:-- --:--:--  162k\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "%load_ext autoreload\n",
        "%autoreload 2\n",
        "\n",
        "#standard libraries\n",
        "import sys\n",
        "sys.path.append('../')\n",
        "\n",
        "import json\n",
        "import os\n",
        "import time\n",
        "from typing import List, Tuple\n",
        "from math import ceil\n",
        "\n",
        "#external libraries\n",
        "import pandas as pd\n",
        "import numpy as np\n",
        "from rich import print\n",
        "from rich.pretty import pprint #nifty library for pretty printing\n",
        "from torch import cuda\n",
        "from tqdm import tqdm\n",
        "\n"
      ],
      "metadata": {
        "id": "rVxDl7MJKs6A"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#root folder on Google Colab is: /content/\n",
        "root_folder = '/content/'  #'../data'\n",
        "data_file = 'Data_Med.json'\n",
        "data_path = os.path.join(root_folder, data_file)\n",
        "data_path"
      ],
      "metadata": {
        "id": "-Y9k7OPOK1Px",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "f8a4e33a-5f9d-4199-d583-c83335954420"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'/content/Data_Med.json'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 4
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def load_json(file_path: str) -> list[dict]:\n",
        "  with open(file_path) as f:\n",
        "    data = json.load(f)\n",
        "  return data\n",
        "\n",
        "data = load_json(data_path)\n",
        "print(f'Total # of papers: {len(data)}')"
      ],
      "metadata": {
        "id": "WtQfbJ9dK70E",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 33
        },
        "outputId": "3e9c6969-46c3-4edc-d38e-80ac46a69ae3"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Total # of papers: \u001b[1;36m14\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\">Total # of papers: <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">14</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(data[0])"
      ],
      "metadata": {
        "id": "4T02-Ng3LCEN",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "collapsed": true,
        "outputId": "e7e7e9eb-1070-43d4-d09c-91f4c97139e0"
      },
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1m{\u001b[0m\n",
              "    \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_1'\u001b[0m,\n",
              "    \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m,\n",
              "    \u001b[32m'content'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic Tests for Diabetes: i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mA1C Prediabetes: \u001b[0m\n",
              "\u001b[32m5.7–6.4% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m39–47 mmol/ mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥6.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥48 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 2-hour glucose value during a 75-g oral glucose \u001b[0m\n",
              "\u001b[32mtolerance test Prediabetes: 140–199 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m7.8–11.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mFasting plasma \u001b[0m\n",
              "\u001b[32mglucose Prediabetes: 100–125 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.6–6.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥126 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥7.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mRandom glucose value with\u001b[0m\n",
              "\u001b[32mclassic hyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • There is insufficient \u001b[0m\n",
              "\u001b[32mevidence to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes. •\u001b[0m\n",
              "\u001b[32mIn the absence of unequivocal hyperglycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hyperglycemic crisis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, diagnosis of type 2 diabetes requires \u001b[0m\n",
              "\u001b[32mconfirmatory testing, which can be a different test on the same day or the same test on a different day. • Marked \u001b[0m\n",
              "\u001b[32mdiscordance between A1C and repeated blood \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Classification Classification of diabetes type is not always \u001b[0m\n",
              "\u001b[32mstraightforward at presentation, and misdiagnosis is common. i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 1 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32midiopathic or autoimmune β-cell \u001b[0m\n",
              "\u001b[32mdestruction\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 2 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mnon-autoimmune progressive loss of adequate β-cell insulin secretion frequently on\u001b[0m\n",
              "\u001b[32mthe background of insulin resistance and metabolic syndrome\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mGestational diabetes mellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM; detected at \u001b[0m\n",
              "\u001b[32m24–28 weeks of gestation in individuals without previously identified diabetes or high-risk glucose metabolism\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32miv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mDiabetes from other causes \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., monogenic diabetes syndromes, diseases of the exocrine pancreas, and drug- or \u001b[0m\n",
              "\u001b[32mchemical-induced diabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32mScreening Criteria for Prediabetes and Type 2 Diabetes: Screening for prediabetes and\u001b[0m\n",
              "\u001b[32mtype 2 diabetes should be performed in asymptomatic adults with an informal assessment of risk factors or a \u001b[0m\n",
              "\u001b[32mvalidated risk calculator. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32mInformal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Everyone ≥35 \u001b[0m\n",
              "\u001b[32myears of age ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with prior GDM iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mHistory of prediabetes iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with HIV, exposure to high-risk \u001b[0m\n",
              "\u001b[32mmedicines, or a history of pancreatitis. Adults \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥18 years of age\u001b[0m\u001b[32m)\u001b[0m\u001b[32m with overweight or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥25 kg/m2 or ≥23\u001b[0m\n",
              "\u001b[32mkg/m2 in Asian American individuals\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more of the following risk factors: ʜ First-degree relative \u001b[0m\n",
              "\u001b[32mwith diabetes ʜ High-risk race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥130/80 mmHg or on \u001b[0m\n",
              "\u001b[32mtherapy for hypertension\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ Polycystic ovary syndrome ʜ HDL cholestorol \u001b[0m\u001b[32m<\u001b[0m\u001b[32m35\u001b[0m\u001b[32m mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<0.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and/or \u001b[0m\n",
              "\u001b[32mtrigylcerides >250 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m>\u001b[0m\u001b[32m2.8 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ Physical inactivity ʜ Other clinical conditions associated with insulin \u001b[0m\n",
              "\u001b[32mresistance \u001b[0m\u001b[32m(\u001b[0m\u001b[32mE\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Clinical Notes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m If results are normal, repeat screening at least every 3 years \u001b[0m\u001b[32m(\u001b[0m\u001b[32mannually for those\u001b[0m\n",
              "\u001b[32mwith prediabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, or sooner with symptoms or changes in risk. ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Risk-based screening for prediabetes or type 2 \u001b[0m\n",
              "\u001b[32mdiabetes should be considered after the onset of puberty or after 10 years of age, whichever occurs earlier, in \u001b[0m\n",
              "\u001b[32mchildren and adolescents with overweight \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥85th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥95th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or \u001b[0m\n",
              "\u001b[32mmore risk factors for diabetes. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mF\u001b[0m\u001b[32m)\u001b[0m\u001b[32m i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: An altered relationship between A1C and glycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical\u001b[0m\n",
              "\u001b[32mtips: A mismatch between A1C and glycemia could be caused by some hemoglobin variants, pregnancy \u001b[0m\u001b[32m(\u001b[0m\u001b[32msecond and third \u001b[0m\n",
              "\u001b[32mtrimesters and the postpartum period\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent \u001b[0m\n",
              "\u001b[32mblood loss or transfusion, anemia, or erythropoietin therapy. People with HIV should be screened for diabetes and \u001b[0m\n",
              "\u001b[32mprediabetes before and 3–6 months after starting or changing antiretroviral therapy and annually if initial results\u001b[0m\n",
              "\u001b[32mare normal. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Fasting plasmaglucose ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Acute pancreatitis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for\u001b[0m\n",
              "\u001b[32mdiabetes 3-6 months after an episode of acute pancreatitis and annually thereafter. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Any standard \u001b[0m\n",
              "\u001b[32mtest for diagnosing diabetes iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Cystic fibrosis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Annual screening should begin \u001b[0m\n",
              "\u001b[32mby the age of 10 years in all people with cystic fibrosis not previously diagnosed with cystic fibrosis-related \u001b[0m\n",
              "\u001b[32mdiabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Posttransplantation status \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical \u001b[0m\n",
              "\u001b[32mtips: Screen for hyperglycemia after organ transplantation. Posttransplantation diabetes mellitus should be \u001b[0m\n",
              "\u001b[32mdiagnosed when the individual is stable on immunosuppressive therapy and free of acute infections. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: \u001b[0m\n",
              "\u001b[32mOral glucose tolerance test v\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Possible monogenic diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Suspect monogenic \u001b[0m\n",
              "\u001b[32mdiabetes in people diagnosed with diabetes in the first 6 months of life and in children and young adults with \u001b[0m\n",
              "\u001b[32matypical characteristics of type 1 or type 2 diabetes, who often have a family history of diabetes in successive \u001b[0m\n",
              "\u001b[32mgenerations \u001b[0m\u001b[32m(\u001b[0m\u001b[32msuggestive of an autosomal dominant pattern of inheritance\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any standard test for \u001b[0m\n",
              "\u001b[32mdiagnosing diabetes plus appropriate genetic testing vi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Therapy with certain medications \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mclinical tips: Consider screening people for prediabetes or diabetes if they are on certain medications known to \u001b[0m\n",
              "\u001b[32mincrease diabetes risk, such as glucocorticoids, statins, thiazide diuretics, some HIV medications, and \u001b[0m\n",
              "\u001b[32msecond-generation antipsychotic medications. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any standard test test for diagnosing diabetes'\u001b[0m,\n",
              "    \u001b[32m'Summary'\u001b[0m: \u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing various \u001b[0m\n",
              "\u001b[32mtests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral glucose \u001b[0m\n",
              "\u001b[32mtolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is diagnosed at \u001b[0m\n",
              "\u001b[32m≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of symptoms. It \u001b[0m\n",
              "\u001b[32mnotes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the necessity \u001b[0m\n",
              "\u001b[32mfor confirmatory testing in ambiguous cases. The classification section details different types of diabetes \u001b[0m\n",
              "\u001b[32mincluding Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is recommended for \u001b[0m\n",
              "\u001b[32madults based on risk factors, with specific guidelines for assessing risks such as age, prior gestational diabetes,\u001b[0m\n",
              "\u001b[32mand other health conditions. Clinical notes suggest repeat screening every three years for normal results, and more\u001b[0m\n",
              "\u001b[32mfrequently for those with prediabetes or changing symptoms. Special circumstances, like hemoglobin variants or \u001b[0m\n",
              "\u001b[32mpost-transplant status, may alter screening methods, with various specific tests recommended based on the \u001b[0m\n",
              "\u001b[32mindividual's condition and risk factors.\"\u001b[0m\n",
              "\u001b[1m}\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"font-weight: bold\">{</span>\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes (A) Diagnostic Tests for Diabetes: i)A1C Prediabetes: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">5.7–6.4% (39–47 mmol/ mol) Diabetes: ≥6.5% (≥48 mmol/mol) ii) 2-hour glucose value during a 75-g oral glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tolerance test Prediabetes: 140–199 mg/dL (7.8–11.0 mmol/L) Diabetes: ≥200 mg/dL (≥11.1 mmol/L) iii)Fasting plasma </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose Prediabetes: 100–125 mg/dL (5.6–6.9 mmol/L) Diabetes: ≥126 mg/dL (≥7.0 mmol/L) iv)Random glucose value with</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">classic hyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL (≥11.1 mmol/L) • There is insufficient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">evidence to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes. •</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">In the absence of unequivocal hyperglycemia (e.g., hyperglycemic crisis), diagnosis of type 2 diabetes requires </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">confirmatory testing, which can be a different test on the same day or the same test on a different day. • Marked </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">discordance between A1C and repeated blood (B) Classification Classification of diabetes type is not always </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">straightforward at presentation, and misdiagnosis is common. i)Type 1 diabetes (idiopathic or autoimmune β-cell </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">destruction) ii)Type 2 diabetes (non-autoimmune progressive loss of adequate β-cell insulin secretion frequently on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the background of insulin resistance and metabolic syndrome) iii)Gestational diabetes mellitus (GDM; detected at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">24–28 weeks of gestation in individuals without previously identified diabetes or high-risk glucose metabolism) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">iv)Diabetes from other causes (e.g., monogenic diabetes syndromes, diseases of the exocrine pancreas, and drug- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">chemical-induced diabetes) (C)Screening Criteria for Prediabetes and Type 2 Diabetes: Screening for prediabetes and</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 2 diabetes should be performed in asymptomatic adults with an informal assessment of risk factors or a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">validated risk calculator. (D)Informal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i) Everyone ≥35 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">years of age ii)People with prior GDM iii)History of prediabetes iv)People with HIV, exposure to high-risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medicines, or a history of pancreatitis. Adults (≥18 years of age) with overweight or obesity (BMI ≥25 kg/m2 or ≥23</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">kg/m2 in Asian American individuals) who have one or more of the following risk factors: ʜ First-degree relative </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with diabetes ʜ High-risk race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension (≥130/80 mmHg or on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy for hypertension) ʜ Polycystic ovary syndrome ʜ HDL cholestorol &lt;35 mg/dL (&lt;0.9 mmol/L) and/or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">trigylcerides &gt;250 mg/dL (&gt;2.8 mmol/L) ʜ Physical inactivity ʜ Other clinical conditions associated with insulin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">resistance (E) Clinical Notes i) If results are normal, repeat screening at least every 3 years (annually for those</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with prediabetes), or sooner with symptoms or changes in risk. ii) Risk-based screening for prediabetes or type 2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes should be considered after the onset of puberty or after 10 years of age, whichever occurs earlier, in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">children and adolescents with overweight (BMI ≥85th percentile) or obesity (BMI ≥95th percentile) who have one or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">more risk factors for diabetes. (F) i) (a) condition: An altered relationship between A1C and glycemia (b) clinical</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tips: A mismatch between A1C and glycemia could be caused by some hemoglobin variants, pregnancy (second and third </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">trimesters and the postpartum period), glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood loss or transfusion, anemia, or erythropoietin therapy. People with HIV should be screened for diabetes and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prediabetes before and 3–6 months after starting or changing antiretroviral therapy and annually if initial results</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are normal. (c) best test:Fasting plasmaglucose ii) (a) condition: Acute pancreatitis (b) clinical tips: Screen for</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes 3-6 months after an episode of acute pancreatitis and annually thereafter. (c) best test: Any standard </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">test for diagnosing diabetes iii) (a) condition: Cystic fibrosis (b) clinical tips: Annual screening should begin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">by the age of 10 years in all people with cystic fibrosis not previously diagnosed with cystic fibrosis-related </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes (c) best test: Oral glucose tolerance test iv) (a) condition: Posttransplantation status (b) clinical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tips: Screen for hyperglycemia after organ transplantation. Posttransplantation diabetes mellitus should be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed when the individual is stable on immunosuppressive therapy and free of acute infections. (c) best test: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Oral glucose tolerance test v) (a) condition: Possible monogenic diabetes (b) clinical tips: Suspect monogenic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes in people diagnosed with diabetes in the first 6 months of life and in children and young adults with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">atypical characteristics of type 1 or type 2 diabetes, who often have a family history of diabetes in successive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">generations (suggestive of an autosomal dominant pattern of inheritance). (c) best test:Any standard test for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosing diabetes plus appropriate genetic testing vi) (a) condition: Therapy with certain medications (b) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">clinical tips: Consider screening people for prediabetes or diabetes if they are on certain medications known to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">increase diabetes risk, such as glucocorticoids, statins, thiazide diuretics, some HIV medications, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">second-generation antipsychotic medications. (c) best test:Any standard test test for diagnosing diabetes'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'Summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing various </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is diagnosed at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of symptoms. It </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the necessity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for confirmatory testing in ambiguous cases. The classification section details different types of diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is recommended for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adults based on risk factors, with specific guidelines for assessing risks such as age, prior gestational diabetes,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and other health conditions. Clinical notes suggest repeat screening every three years for normal results, and more</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">frequently for those with prediabetes or changing symptoms. Special circumstances, like hemoglobin variants or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">post-transplant status, may alter screening methods, with various specific tests recommended based on the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individual's condition and risk factors.\"</span>\n",
              "<span style=\"font-weight: bold\">}</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "contents = [d['content'] for d in data]\n",
        "content_lengths = [len(content.split()) for content in contents]\n",
        "df = pd.DataFrame(content_lengths, columns=['# Words'])\n",
        "df.describe()"
      ],
      "metadata": {
        "id": "wlsV5sHQNjJ5",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 300
        },
        "outputId": "0a6b6467-4da5-4e0c-f13c-0bd4d3449c7f"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "           # Words\n",
              "count    14.000000\n",
              "mean    862.285714\n",
              "std     423.422580\n",
              "min     362.000000\n",
              "25%     639.000000\n",
              "50%     789.500000\n",
              "75%    1025.750000\n",
              "max    2116.000000"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-25e18a82-afd2-41b8-aa9e-2cb6731bf55a\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th># Words</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>count</th>\n",
              "      <td>14.000000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>mean</th>\n",
              "      <td>862.285714</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>std</th>\n",
              "      <td>423.422580</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>min</th>\n",
              "      <td>362.000000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25%</th>\n",
              "      <td>639.000000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50%</th>\n",
              "      <td>789.500000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>75%</th>\n",
              "      <td>1025.750000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>max</th>\n",
              "      <td>2116.000000</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-25e18a82-afd2-41b8-aa9e-2cb6731bf55a')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-25e18a82-afd2-41b8-aa9e-2cb6731bf55a button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-25e18a82-afd2-41b8-aa9e-2cb6731bf55a');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-1a61264d-804c-441d-a885-b081a763878d\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-1a61264d-804c-441d-a885-b081a763878d')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-1a61264d-804c-441d-a885-b081a763878d button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 8,\n  \"fields\": [\n    {\n      \"column\": \"# Words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 627.9957488534548,\n        \"min\": 14.0,\n        \"max\": 2116.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          862.2857142857143,\n          789.5,\n          14.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(contents[:2])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "collapsed": true,
        "id": "GoKYZ7LZaL_I",
        "outputId": "bd0910ad-b7fc-43d8-91c5-cf12420ed621"
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1m[\u001b[0m\n",
              "    \u001b[32m'Diagnosis and Classification of Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic Tests for Diabetes: i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mA1C Prediabetes: 5.7–6.4% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m39–47\u001b[0m\n",
              "\u001b[32mmmol/ mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥6.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥48 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 2-hour glucose value during a 75-g oral glucose tolerance test \u001b[0m\n",
              "\u001b[32mPrediabetes: 140–199 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m7.8–11.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mFasting plasma glucose \u001b[0m\n",
              "\u001b[32mPrediabetes: 100–125 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.6–6.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥126 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥7.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mRandom glucose value with classic\u001b[0m\n",
              "\u001b[32mhyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • There is insufficient evidence \u001b[0m\n",
              "\u001b[32mto support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes. • In the \u001b[0m\n",
              "\u001b[32mabsence of unequivocal hyperglycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hyperglycemic crisis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, diagnosis of type 2 diabetes requires \u001b[0m\n",
              "\u001b[32mconfirmatory testing, which can be a different test on the same day or the same test on a different day. • Marked \u001b[0m\n",
              "\u001b[32mdiscordance between A1C and repeated blood \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Classification Classification of diabetes type is not always \u001b[0m\n",
              "\u001b[32mstraightforward at presentation, and misdiagnosis is common. i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 1 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32midiopathic or autoimmune β-cell \u001b[0m\n",
              "\u001b[32mdestruction\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 2 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mnon-autoimmune progressive loss of adequate β-cell insulin secretion frequently on\u001b[0m\n",
              "\u001b[32mthe background of insulin resistance and metabolic syndrome\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mGestational diabetes mellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM; detected at \u001b[0m\n",
              "\u001b[32m24–28 weeks of gestation in individuals without previously identified diabetes or high-risk glucose metabolism\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32miv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mDiabetes from other causes \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., monogenic diabetes syndromes, diseases of the exocrine pancreas, and drug- or \u001b[0m\n",
              "\u001b[32mchemical-induced diabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32mScreening Criteria for Prediabetes and Type 2 Diabetes: Screening for prediabetes and\u001b[0m\n",
              "\u001b[32mtype 2 diabetes should be performed in asymptomatic adults with an informal assessment of risk factors or a \u001b[0m\n",
              "\u001b[32mvalidated risk calculator. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32mInformal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Everyone ≥35 \u001b[0m\n",
              "\u001b[32myears of age ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with prior GDM iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mHistory of prediabetes iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with HIV, exposure to high-risk \u001b[0m\n",
              "\u001b[32mmedicines, or a history of pancreatitis. Adults \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥18 years of age\u001b[0m\u001b[32m)\u001b[0m\u001b[32m with overweight or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥25 kg/m2 or ≥23\u001b[0m\n",
              "\u001b[32mkg/m2 in Asian American individuals\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more of the following risk factors: ʜ First-degree relative \u001b[0m\n",
              "\u001b[32mwith diabetes ʜ High-risk race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥130/80 mmHg or on \u001b[0m\n",
              "\u001b[32mtherapy for hypertension\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ Polycystic ovary syndrome ʜ HDL cholestorol \u001b[0m\u001b[32m<\u001b[0m\u001b[32m35\u001b[0m\u001b[32m mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<0.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and/or \u001b[0m\n",
              "\u001b[32mtrigylcerides >250 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m>\u001b[0m\u001b[32m2.8 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ Physical inactivity ʜ Other clinical conditions associated with insulin \u001b[0m\n",
              "\u001b[32mresistance \u001b[0m\u001b[32m(\u001b[0m\u001b[32mE\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Clinical Notes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m If results are normal, repeat screening at least every 3 years \u001b[0m\u001b[32m(\u001b[0m\u001b[32mannually for those\u001b[0m\n",
              "\u001b[32mwith prediabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, or sooner with symptoms or changes in risk. ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Risk-based screening for prediabetes or type 2 \u001b[0m\n",
              "\u001b[32mdiabetes should be considered after the onset of puberty or after 10 years of age, whichever occurs earlier, in \u001b[0m\n",
              "\u001b[32mchildren and adolescents with overweight \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥85th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥95th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or \u001b[0m\n",
              "\u001b[32mmore risk factors for diabetes. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mF\u001b[0m\u001b[32m)\u001b[0m\u001b[32m i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: An altered relationship between A1C and glycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical\u001b[0m\n",
              "\u001b[32mtips: A mismatch between A1C and glycemia could be caused by some hemoglobin variants, pregnancy \u001b[0m\u001b[32m(\u001b[0m\u001b[32msecond and third \u001b[0m\n",
              "\u001b[32mtrimesters and the postpartum period\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent \u001b[0m\n",
              "\u001b[32mblood loss or transfusion, anemia, or erythropoietin therapy. People with HIV should be screened for diabetes and \u001b[0m\n",
              "\u001b[32mprediabetes before and 3–6 months after starting or changing antiretroviral therapy and annually if initial results\u001b[0m\n",
              "\u001b[32mare normal. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Fasting plasmaglucose ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Acute pancreatitis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for\u001b[0m\n",
              "\u001b[32mdiabetes 3-6 months after an episode of acute pancreatitis and annually thereafter. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Any standard \u001b[0m\n",
              "\u001b[32mtest for diagnosing diabetes iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Cystic fibrosis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Annual screening should begin \u001b[0m\n",
              "\u001b[32mby the age of 10 years in all people with cystic fibrosis not previously diagnosed with cystic fibrosis-related \u001b[0m\n",
              "\u001b[32mdiabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Posttransplantation status \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical \u001b[0m\n",
              "\u001b[32mtips: Screen for hyperglycemia after organ transplantation. Posttransplantation diabetes mellitus should be \u001b[0m\n",
              "\u001b[32mdiagnosed when the individual is stable on immunosuppressive therapy and free of acute infections. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: \u001b[0m\n",
              "\u001b[32mOral glucose tolerance test v\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Possible monogenic diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Suspect monogenic \u001b[0m\n",
              "\u001b[32mdiabetes in people diagnosed with diabetes in the first 6 months of life and in children and young adults with \u001b[0m\n",
              "\u001b[32matypical characteristics of type 1 or type 2 diabetes, who often have a family history of diabetes in successive \u001b[0m\n",
              "\u001b[32mgenerations \u001b[0m\u001b[32m(\u001b[0m\u001b[32msuggestive of an autosomal dominant pattern of inheritance\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any standard test for \u001b[0m\n",
              "\u001b[32mdiagnosing diabetes plus appropriate genetic testing vi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Therapy with certain medications \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mclinical tips: Consider screening people for prediabetes or diabetes if they are on certain medications known to \u001b[0m\n",
              "\u001b[32mincrease diabetes risk, such as glucocorticoids, statins, thiazide diuretics, some HIV medications, and \u001b[0m\n",
              "\u001b[32msecond-generation antipsychotic medications. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any standard test test for diagnosing diabetes'\u001b[0m,\n",
              "    \u001b[32m'Prevention or Delay of Diabetes and Associated Comorbidities \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screening for Type 2 Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Why Screen?\u001b[0m\n",
              "\u001b[32m• Lab testing is safe and cost- effective. • Screening presents an opportunity to address cardiovascular risk \u001b[0m\n",
              "\u001b[32mfactors \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hypertension and dyslipidemia\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 2. How to Screen • Conduct an informal assessment of risk \u001b[0m\n",
              "\u001b[32mfactors. –or– • Use an assessment tool such as the ADA risk test. • Consider diagnostic testing based on assessment\u001b[0m\n",
              "\u001b[32mresults. \u001b[0m\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When to Screen • Monitor people with prediabetes at least annually. • In those without prediabetes \u001b[0m\n",
              "\u001b[32mwho have normal results, repeat screening at least every 3 years. • Screen after the onset of puberty or after the \u001b[0m\n",
              "\u001b[32mage of 10 years in children and adolescents with overweight \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥85th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥95th \u001b[0m\n",
              "\u001b[32mpercentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have at least one risk factor. • Symptoms suggestive of diabetes or changes in risk \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diet and \u001b[0m\n",
              "\u001b[32mPhysical Activity Recommendations for Adults at Risk for Type 2 Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Follow a Healthy Eating Pattern • \u001b[0m\n",
              "\u001b[32mEmphasize whole grains, legumes, nuts, fruits, and vegetables and minimize refined and processed foods • A variety \u001b[0m\n",
              "\u001b[32mof healthy eating patterns include: » Mediterranean-style » Low-carbohydrate » Vegetarian or plant-based » DASH \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mDietary Approaches to Stop Hypertension\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Get Regular Physical Activity • ≥150 min/week of moderate-intensity \u001b[0m\n",
              "\u001b[32mphysical activity, such as brisk walking • May include resistance or strength training • Break up prolonged \u001b[0m\n",
              "\u001b[32msedentary time \u001b[0m\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Where to Refer: • Refer adults with overweight or obesity who are at high risk for type 2 \u001b[0m\n",
              "\u001b[32mdiabetes to a recognized diabetes prevention lifestyle change program \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mcdc.gov/diabetes/prevention/find-a-program.html\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\u001b[32m(\u001b[0m\u001b[32miv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m What is the Diabetes Prevention Program? • The Diabetes \u001b[0m\n",
              "\u001b[32mPrevention Program \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDPP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m study demonstrated that intensive lifestyle intervention could reduce the risk of type \u001b[0m\n",
              "\u001b[32mdiabetes by 58% over 3 years. The two major goals of the DPP intensive lifestyle intervention were to achieve and \u001b[0m\n",
              "\u001b[32mmaintain ≥7% weight loss and ≥150 min of moderate-intensity physical activity, such as brisk walking, per week. \u001b[0m\n",
              "\u001b[32mTechnology-assisted programs using smartphones, web apps, and telehealth platforms can effectively deliver the DPP \u001b[0m\n",
              "\u001b[32mlifestyle change program, overcoming barriers, especially for low-income and rural individuals. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Person-Centered\u001b[0m\n",
              "\u001b[32mCare Goals for Individuals at Risk of Type 2 Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m It is important to weight the individualized risks and \u001b[0m\n",
              "\u001b[32mbenefits of interventions. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Facilitate weight management in those with overweight/obesity. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Minimize \u001b[0m\n",
              "\u001b[32mprogression of hyperglycemia. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m3\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Reduce cardiovascular risk. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Consider more intensive approaches for \u001b[0m\n",
              "\u001b[32mindividuals at high risk of progression to diabetes. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m BMI ≥35 kg/m2 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Higher glucose levels \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., fasting \u001b[0m\n",
              "\u001b[32mplasma glucose 110–125 mg/dL \u001b[0m\u001b[32m[\u001b[0m\u001b[32m6.1–6.9 mmol/L\u001b[0m\u001b[32m]\u001b[0m\u001b[32m, 2–h post-challenge glucose 173 199 mg/dL \u001b[0m\u001b[32m[\u001b[0m\u001b[32m9.6–11 mmol/L\u001b[0m\u001b[32m]\u001b[0m\u001b[32m, and A1C \u001b[0m\n",
              "\u001b[32m≥6.0% \u001b[0m\u001b[32m[\u001b[0m\u001b[32m42 mmol/mol\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32m3\u001b[0m\u001b[32m)\u001b[0m\u001b[32m History of gestational diabetes mellitus What medications can be prescribed to adults to \u001b[0m\n",
              "\u001b[32mprevent type 2 diabetes? The U.S. Food and Drug Administration has not approved any drugs for diabetes prevention. \u001b[0m\n",
              "\u001b[32mMetformin has the strongest evidence base for diabetes prevention. Who should be considered for metformin therapy \u001b[0m\n",
              "\u001b[32mto prevent type 2 diabetes? i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Adults aged 25–59 years with a BMI ≥35 kg/m2 ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Individuals with higher fasting \u001b[0m\n",
              "\u001b[32mplasma glucose \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., ≥110 mg/dL \u001b[0m\u001b[32m[\u001b[0m\u001b[32m≥ 6 mmol/L\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Those with higher A1C \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., ≥6.0% \u001b[0m\u001b[32m[\u001b[0m\u001b[32m≥42 mmol/mol\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mIndividuals with a history of gestational diabetes mellitus What parameters should be monitoring in people on \u001b[0m\n",
              "\u001b[32mmetformin therapy? i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Vitamin B12 should be measured periodically, especially in those with anemia or peripheral \u001b[0m\n",
              "\u001b[32mneuropathy. Screening for type 1 diabetes? 1. Screen using autoantibodies 2. In people with preclinical type 1 \u001b[0m\n",
              "\u001b[32mdiabetes, monitor for disease progression using A1C approximately every 6 months and 75-g oral glucose tolerance \u001b[0m\n",
              "\u001b[32mtest \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi.e., fasting and 2-h plasma glucose\u001b[0m\u001b[32m)\u001b[0m\u001b[32m annually; modify frequency of monitoring based on individual risk \u001b[0m\n",
              "\u001b[32massessment based on age, number and type of autoantibodies, and glycemic metrics. Medication to delay the onset of \u001b[0m\n",
              "\u001b[32mtype 1 diabetes Teplizumab-mzwv infusion to delay the onset of symptomatic type 1 diabetes should be considered in \u001b[0m\n",
              "\u001b[32mselected individuals who are ≥8 years of age and have stage 2 type 1 diabetes. Staging of type 1 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Stage\u001b[0m\n",
              "\u001b[32m1 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Characteristics: • Autoimmunity • Normoglycemia • Presymptomatic \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic criteria : • Multiple islet \u001b[0m\n",
              "\u001b[32mautoantibodies • No IGT or IFG \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Stage 2 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Characteristics: • Autoimmunity • Dysglycemia • Presymptomatic \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mDiagnostic criteria : • Islet autoantibodies \u001b[0m\u001b[32m(\u001b[0m\u001b[32musually multiple\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • Dysglycemia: IFG and/or IGT • FPG 100–125 mg/dl \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m5.6–6.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • 2-h PG 140–199 mg/dl \u001b[0m\u001b[32m(\u001b[0m\u001b[32m7.8–11.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • A1C 5.7–6.4% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m39–47 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or ≥10% increase in A1C \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Stage 3 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Characteristics: • Autoimmunity • Overt hyperglycemia • Symptomatic \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic criteria : • \u001b[0m\n",
              "\u001b[32mAutoantibodies may become absent • Diabetes by Does statin therapy increase the risk of developing type 2 diabetes?\u001b[0m\n",
              "\u001b[32m• Statin therapy may slightly elevate type 2 diabetes risk in high-risk individuals. • In primary and secondary \u001b[0m\n",
              "\u001b[32mprevention of cardiovascular disease, statin benefits outweigh diabetes risk. • Discontinuing statins based on \u001b[0m\n",
              "\u001b[32mconcerns about increased diabetes risk is not advised. Does pioglitazone have a role in secondary cardiovascular \u001b[0m\n",
              "\u001b[32mprevention in people at risk for type 2 diabetes? Pioglitazone could reduce stroke and myocardial infarction risks \u001b[0m\n",
              "\u001b[32min people with a history of stroke and evidence of insulin resistance or prediabetes. However, the benefit must be \u001b[0m\n",
              "\u001b[32mweighed against potential weight gain, edema, and increased fracture risk. Lower doses may lessen these adverse \u001b[0m\n",
              "\u001b[32meffects.'\u001b[0m\n",
              "\u001b[1m]\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"font-weight: bold\">[</span>\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes (A) Diagnostic Tests for Diabetes: i)A1C Prediabetes: 5.7–6.4% (39–47</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mmol/ mol) Diabetes: ≥6.5% (≥48 mmol/mol) ii) 2-hour glucose value during a 75-g oral glucose tolerance test </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Prediabetes: 140–199 mg/dL (7.8–11.0 mmol/L) Diabetes: ≥200 mg/dL (≥11.1 mmol/L) iii)Fasting plasma glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Prediabetes: 100–125 mg/dL (5.6–6.9 mmol/L) Diabetes: ≥126 mg/dL (≥7.0 mmol/L) iv)Random glucose value with classic</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL (≥11.1 mmol/L) • There is insufficient evidence </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes. • In the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">absence of unequivocal hyperglycemia (e.g., hyperglycemic crisis), diagnosis of type 2 diabetes requires </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">confirmatory testing, which can be a different test on the same day or the same test on a different day. • Marked </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">discordance between A1C and repeated blood (B) Classification Classification of diabetes type is not always </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">straightforward at presentation, and misdiagnosis is common. i)Type 1 diabetes (idiopathic or autoimmune β-cell </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">destruction) ii)Type 2 diabetes (non-autoimmune progressive loss of adequate β-cell insulin secretion frequently on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the background of insulin resistance and metabolic syndrome) iii)Gestational diabetes mellitus (GDM; detected at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">24–28 weeks of gestation in individuals without previously identified diabetes or high-risk glucose metabolism) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">iv)Diabetes from other causes (e.g., monogenic diabetes syndromes, diseases of the exocrine pancreas, and drug- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">chemical-induced diabetes) (C)Screening Criteria for Prediabetes and Type 2 Diabetes: Screening for prediabetes and</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 2 diabetes should be performed in asymptomatic adults with an informal assessment of risk factors or a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">validated risk calculator. (D)Informal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i) Everyone ≥35 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">years of age ii)People with prior GDM iii)History of prediabetes iv)People with HIV, exposure to high-risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medicines, or a history of pancreatitis. Adults (≥18 years of age) with overweight or obesity (BMI ≥25 kg/m2 or ≥23</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">kg/m2 in Asian American individuals) who have one or more of the following risk factors: ʜ First-degree relative </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with diabetes ʜ High-risk race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension (≥130/80 mmHg or on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy for hypertension) ʜ Polycystic ovary syndrome ʜ HDL cholestorol &lt;35 mg/dL (&lt;0.9 mmol/L) and/or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">trigylcerides &gt;250 mg/dL (&gt;2.8 mmol/L) ʜ Physical inactivity ʜ Other clinical conditions associated with insulin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">resistance (E) Clinical Notes i) If results are normal, repeat screening at least every 3 years (annually for those</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with prediabetes), or sooner with symptoms or changes in risk. ii) Risk-based screening for prediabetes or type 2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes should be considered after the onset of puberty or after 10 years of age, whichever occurs earlier, in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">children and adolescents with overweight (BMI ≥85th percentile) or obesity (BMI ≥95th percentile) who have one or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">more risk factors for diabetes. (F) i) (a) condition: An altered relationship between A1C and glycemia (b) clinical</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tips: A mismatch between A1C and glycemia could be caused by some hemoglobin variants, pregnancy (second and third </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">trimesters and the postpartum period), glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood loss or transfusion, anemia, or erythropoietin therapy. People with HIV should be screened for diabetes and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prediabetes before and 3–6 months after starting or changing antiretroviral therapy and annually if initial results</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are normal. (c) best test:Fasting plasmaglucose ii) (a) condition: Acute pancreatitis (b) clinical tips: Screen for</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes 3-6 months after an episode of acute pancreatitis and annually thereafter. (c) best test: Any standard </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">test for diagnosing diabetes iii) (a) condition: Cystic fibrosis (b) clinical tips: Annual screening should begin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">by the age of 10 years in all people with cystic fibrosis not previously diagnosed with cystic fibrosis-related </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes (c) best test: Oral glucose tolerance test iv) (a) condition: Posttransplantation status (b) clinical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tips: Screen for hyperglycemia after organ transplantation. Posttransplantation diabetes mellitus should be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed when the individual is stable on immunosuppressive therapy and free of acute infections. (c) best test: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Oral glucose tolerance test v) (a) condition: Possible monogenic diabetes (b) clinical tips: Suspect monogenic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes in people diagnosed with diabetes in the first 6 months of life and in children and young adults with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">atypical characteristics of type 1 or type 2 diabetes, who often have a family history of diabetes in successive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">generations (suggestive of an autosomal dominant pattern of inheritance). (c) best test:Any standard test for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosing diabetes plus appropriate genetic testing vi) (a) condition: Therapy with certain medications (b) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">clinical tips: Consider screening people for prediabetes or diabetes if they are on certain medications known to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">increase diabetes risk, such as glucocorticoids, statins, thiazide diuretics, some HIV medications, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">second-generation antipsychotic medications. (c) best test:Any standard test test for diagnosing diabetes'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'Prevention or Delay of Diabetes and Associated Comorbidities (A) Screening for Type 2 Diabetes (i) Why Screen?</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">• Lab testing is safe and cost- effective. • Screening presents an opportunity to address cardiovascular risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">factors (e.g., hypertension and dyslipidemia). (ii) 2. How to Screen • Conduct an informal assessment of risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">factors. –or– • Use an assessment tool such as the ADA risk test. • Consider diagnostic testing based on assessment</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">results. (iii) When to Screen • Monitor people with prediabetes at least annually. • In those without prediabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">who have normal results, repeat screening at least every 3 years. • Screen after the onset of puberty or after the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">age of 10 years in children and adolescents with overweight (BMI ≥85th percentile) or obesity (BMI ≥95th </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">percentile) who have at least one risk factor. • Symptoms suggestive of diabetes or changes in risk (B) Diet and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Physical Activity Recommendations for Adults at Risk for Type 2 Diabetes (i) Follow a Healthy Eating Pattern • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Emphasize whole grains, legumes, nuts, fruits, and vegetables and minimize refined and processed foods • A variety </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of healthy eating patterns include: » Mediterranean-style » Low-carbohydrate » Vegetarian or plant-based » DASH </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(Dietary Approaches to Stop Hypertension) (ii) Get Regular Physical Activity • ≥150 min/week of moderate-intensity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">physical activity, such as brisk walking • May include resistance or strength training • Break up prolonged </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">sedentary time (iii) Where to Refer: • Refer adults with overweight or obesity who are at high risk for type 2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes to a recognized diabetes prevention lifestyle change program </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(cdc.gov/diabetes/prevention/find-a-program.html). (iv) What is the Diabetes Prevention Program? • The Diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Prevention Program (DPP) study demonstrated that intensive lifestyle intervention could reduce the risk of type </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes by 58% over 3 years. The two major goals of the DPP intensive lifestyle intervention were to achieve and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintain ≥7% weight loss and ≥150 min of moderate-intensity physical activity, such as brisk walking, per week. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Technology-assisted programs using smartphones, web apps, and telehealth platforms can effectively deliver the DPP </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">lifestyle change program, overcoming barriers, especially for low-income and rural individuals. (C) Person-Centered</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Care Goals for Individuals at Risk of Type 2 Diabetes (i) It is important to weight the individualized risks and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">benefits of interventions. (1) Facilitate weight management in those with overweight/obesity. (2) Minimize </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">progression of hyperglycemia. (3) Reduce cardiovascular risk. (ii) Consider more intensive approaches for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individuals at high risk of progression to diabetes. (1) BMI ≥35 kg/m2 (2) Higher glucose levels (e.g., fasting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plasma glucose 110–125 mg/dL [6.1–6.9 mmol/L], 2–h post-challenge glucose 173 199 mg/dL [9.6–11 mmol/L], and A1C </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">≥6.0% [42 mmol/mol]) (3) History of gestational diabetes mellitus What medications can be prescribed to adults to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prevent type 2 diabetes? The U.S. Food and Drug Administration has not approved any drugs for diabetes prevention. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metformin has the strongest evidence base for diabetes prevention. Who should be considered for metformin therapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to prevent type 2 diabetes? i) Adults aged 25–59 years with a BMI ≥35 kg/m2 ii) Individuals with higher fasting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plasma glucose (e.g., ≥110 mg/dL [≥ 6 mmol/L]) iii) Those with higher A1C (e.g., ≥6.0% [≥42 mmol/mol]) iv) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Individuals with a history of gestational diabetes mellitus What parameters should be monitoring in people on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">metformin therapy? i) Vitamin B12 should be measured periodically, especially in those with anemia or peripheral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">neuropathy. Screening for type 1 diabetes? 1. Screen using autoantibodies 2. In people with preclinical type 1 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes, monitor for disease progression using A1C approximately every 6 months and 75-g oral glucose tolerance </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">test (i.e., fasting and 2-h plasma glucose) annually; modify frequency of monitoring based on individual risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment based on age, number and type of autoantibodies, and glycemic metrics. Medication to delay the onset of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 1 diabetes Teplizumab-mzwv infusion to delay the onset of symptomatic type 1 diabetes should be considered in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">selected individuals who are ≥8 years of age and have stage 2 type 1 diabetes. Staging of type 1 diabetes (i) Stage</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">1 (1) Characteristics: • Autoimmunity • Normoglycemia • Presymptomatic (2) Diagnostic criteria : • Multiple islet </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">autoantibodies • No IGT or IFG (ii) Stage 2 (1) Characteristics: • Autoimmunity • Dysglycemia • Presymptomatic (2) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Diagnostic criteria : • Islet autoantibodies (usually multiple) • Dysglycemia: IFG and/or IGT • FPG 100–125 mg/dl </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(5.6–6.9 mmol/L) • 2-h PG 140–199 mg/dl (7.8–11.0 mmol/L) • A1C 5.7–6.4% (39–47 mmol/mol) or ≥10% increase in A1C </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(iii) Stage 3 (1) Characteristics: • Autoimmunity • Overt hyperglycemia • Symptomatic (2) Diagnostic criteria : • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Autoantibodies may become absent • Diabetes by Does statin therapy increase the risk of developing type 2 diabetes?</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">• Statin therapy may slightly elevate type 2 diabetes risk in high-risk individuals. • In primary and secondary </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prevention of cardiovascular disease, statin benefits outweigh diabetes risk. • Discontinuing statins based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">concerns about increased diabetes risk is not advised. Does pioglitazone have a role in secondary cardiovascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prevention in people at risk for type 2 diabetes? Pioglitazone could reduce stroke and myocardial infarction risks </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">in people with a history of stroke and evidence of insulin resistance or prediabetes. However, the benefit must be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">weighed against potential weight gain, edema, and increased fracture risk. Lower doses may lessen these adverse </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effects.'</span>\n",
              "<span style=\"font-weight: bold\">]</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import tiktoken # tokenizer library for use with OpenAI LLMs\n",
        "\n",
        "#instantiate tokenizer for use with ChatGPT-3.5-Turbo\n",
        "encoding = tiktoken.encoding_for_model('gpt-3.5-turbo-0125')"
      ],
      "metadata": {
        "id": "XIs6ctfxc2mf"
      },
      "execution_count": 9,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Tokenisation not needed for chroma\n",
        "from llama_index.text_splitter import SentenceSplitter #one of the best on the market\n",
        "\n",
        "#set chunk size and instantiate your SentenceSplitter\n",
        "chunk_size = 256\n",
        "gpt35_txt_splitter = SentenceSplitter(chunk_size=chunk_size, tokenizer=encoding.encode, chunk_overlap=0)\n"
      ],
      "metadata": {
        "id": "UcczfWPfQker"
      },
      "execution_count": 10,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def split_contents(corpus: list[dict],\n",
        "                   text_splitter: SentenceSplitter,\n",
        "                   content_field: str='content'\n",
        "                   ) -> list[list[str]]:\n",
        "\n",
        "    return [text_splitter.split_text(d[content_field]) for d in corpus]\n"
      ],
      "metadata": {
        "id": "jf7-DAXIazSa"
      },
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "content_splits = split_contents(data, gpt35_txt_splitter,'content')\n",
        "print(content_splits[0])"
      ],
      "metadata": {
        "collapsed": true,
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 865
        },
        "id": "xF0uG_AHa00U",
        "outputId": "34543769-ef2d-41ee-db9b-f2720c256146"
      },
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1m[\u001b[0m\n",
              "    \u001b[32m'Diagnosis and Classification of Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic Tests for Diabetes: i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mA1C Prediabetes: 5.7–6.4% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m39–47\u001b[0m\n",
              "\u001b[32mmmol/ mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥6.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥48 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 2-hour glucose value during a 75-g oral glucose tolerance test \u001b[0m\n",
              "\u001b[32mPrediabetes: 140–199 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m7.8–11.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mFasting plasma glucose \u001b[0m\n",
              "\u001b[32mPrediabetes: 100–125 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.6–6.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥126 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥7.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mRandom glucose value with classic\u001b[0m\n",
              "\u001b[32mhyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • There is insufficient evidence \u001b[0m\n",
              "\u001b[32mto support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.'\u001b[0m,\n",
              "    \u001b[32m'• In the absence of unequivocal hyperglycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hyperglycemic crisis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, diagnosis of type 2 diabetes \u001b[0m\n",
              "\u001b[32mrequires confirmatory testing, which can be a different test on the same day or the same test on a different day. •\u001b[0m\n",
              "\u001b[32mMarked discordance between A1C and repeated blood \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Classification Classification of diabetes type is not always \u001b[0m\n",
              "\u001b[32mstraightforward at presentation, and misdiagnosis is common. i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 1 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32midiopathic or autoimmune β-cell \u001b[0m\n",
              "\u001b[32mdestruction\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 2 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mnon-autoimmune progressive loss of adequate β-cell insulin secretion frequently on\u001b[0m\n",
              "\u001b[32mthe background of insulin resistance and metabolic syndrome\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mGestational diabetes mellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM; detected at \u001b[0m\n",
              "\u001b[32m24–28 weeks of gestation in individuals without previously identified diabetes or high-risk glucose metabolism\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32miv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mDiabetes from other causes \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., monogenic diabetes syndromes, diseases of the exocrine pancreas, and drug- or \u001b[0m\n",
              "\u001b[32mchemical-induced diabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32mScreening Criteria for Prediabetes and Type 2 Diabetes: Screening for prediabetes and\u001b[0m\n",
              "\u001b[32mtype 2 diabetes should be performed in asymptomatic adults with an informal assessment of risk factors or a \u001b[0m\n",
              "\u001b[32mvalidated risk calculator.'\u001b[0m,\n",
              "    \u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32mInformal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Everyone ≥35 years of age ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople \u001b[0m\n",
              "\u001b[32mwith prior GDM iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mHistory of prediabetes iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with HIV, exposure to high-risk medicines, or a history of \u001b[0m\n",
              "\u001b[32mpancreatitis. Adults \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥18 years of age\u001b[0m\u001b[32m)\u001b[0m\u001b[32m with overweight or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥25 kg/m2 or ≥23 kg/m2 in Asian American \u001b[0m\n",
              "\u001b[32mindividuals\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more of the following risk factors: ʜ First-degree relative with diabetes ʜ High-risk \u001b[0m\n",
              "\u001b[32mrace/ethnicity ʜ History of cardiovascular disease ʜ Hypertension \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥130/80 mmHg or on therapy for hypertension\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ \u001b[0m\n",
              "\u001b[32mPolycystic ovary syndrome ʜ HDL cholestorol \u001b[0m\u001b[32m<\u001b[0m\u001b[32m35\u001b[0m\u001b[32m mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<0.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and/or trigylcerides >250 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m>\u001b[0m\u001b[32m2.8 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ\u001b[0m\n",
              "\u001b[32mPhysical inactivity ʜ Other clinical conditions associated with insulin resistance \u001b[0m\u001b[32m(\u001b[0m\u001b[32mE\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Clinical Notes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m If results\u001b[0m\n",
              "\u001b[32mare normal, repeat screening at least every 3 years \u001b[0m\u001b[32m(\u001b[0m\u001b[32mannually for those with prediabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, or sooner with symptoms \u001b[0m\n",
              "\u001b[32mor changes in risk.'\u001b[0m,\n",
              "    \u001b[32m'ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Risk-based screening for prediabetes or type 2 diabetes should be considered after the onset of puberty or\u001b[0m\n",
              "\u001b[32mafter 10 years of age, whichever occurs earlier, in children and adolescents with overweight \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥85th percentile\u001b[0m\u001b[32m)\u001b[0m\n",
              "\u001b[32mor obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥95th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more risk factors for diabetes. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mF\u001b[0m\u001b[32m)\u001b[0m\u001b[32m i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: An altered \u001b[0m\n",
              "\u001b[32mrelationship between A1C and glycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: A mismatch between A1C and glycemia could be caused by \u001b[0m\n",
              "\u001b[32msome hemoglobin variants, pregnancy \u001b[0m\u001b[32m(\u001b[0m\u001b[32msecond and third trimesters and the postpartum period\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, glucose-6-phosphate \u001b[0m\n",
              "\u001b[32mdehydrogenase deficiency, HIV, hemodialysis, recent blood loss or transfusion, anemia, or erythropoietin therapy. \u001b[0m\n",
              "\u001b[32mPeople with HIV should be screened for diabetes and prediabetes before and 3–6 months after starting or changing \u001b[0m\n",
              "\u001b[32mantiretroviral therapy and annually if initial results are normal. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Fasting plasmaglucose ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mcondition: Acute pancreatitis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for diabetes 3-6 months after an episode of acute \u001b[0m\n",
              "\u001b[32mpancreatitis and annually thereafter.'\u001b[0m,\n",
              "    \u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Any standard test for diagnosing diabetes iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Cystic fibrosis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical \u001b[0m\n",
              "\u001b[32mtips: Annual screening should begin by the age of 10 years in all people with cystic fibrosis not previously \u001b[0m\n",
              "\u001b[32mdiagnosed with cystic fibrosis-related diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: \u001b[0m\n",
              "\u001b[32mPosttransplantation status \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for hyperglycemia after organ transplantation. \u001b[0m\n",
              "\u001b[32mPosttransplantation diabetes mellitus should be diagnosed when the individual is stable on immunosuppressive \u001b[0m\n",
              "\u001b[32mtherapy and free of acute infections. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test v\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Possible \u001b[0m\n",
              "\u001b[32mmonogenic diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Suspect monogenic diabetes in people diagnosed with diabetes in the first 6 \u001b[0m\n",
              "\u001b[32mmonths of life and in children and young adults with atypical characteristics of type 1 or type 2 diabetes, who \u001b[0m\n",
              "\u001b[32moften have a family history of diabetes in successive generations \u001b[0m\u001b[32m(\u001b[0m\u001b[32msuggestive of an autosomal dominant pattern of \u001b[0m\n",
              "\u001b[32minheritance\u001b[0m\u001b[32m)\u001b[0m\u001b[32m.'\u001b[0m,\n",
              "    \u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any standard test for diagnosing diabetes plus appropriate genetic testing vi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: \u001b[0m\n",
              "\u001b[32mTherapy with certain medications \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Consider screening people for prediabetes or diabetes if they \u001b[0m\n",
              "\u001b[32mare on certain medications known to increase diabetes risk, such as glucocorticoids, statins, thiazide diuretics, \u001b[0m\n",
              "\u001b[32msome HIV medications, and second-generation antipsychotic medications. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any standard test test for \u001b[0m\n",
              "\u001b[32mdiagnosing diabetes'\u001b[0m\n",
              "\u001b[1m]\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"font-weight: bold\">[</span>\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes (A) Diagnostic Tests for Diabetes: i)A1C Prediabetes: 5.7–6.4% (39–47</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mmol/ mol) Diabetes: ≥6.5% (≥48 mmol/mol) ii) 2-hour glucose value during a 75-g oral glucose tolerance test </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Prediabetes: 140–199 mg/dL (7.8–11.0 mmol/L) Diabetes: ≥200 mg/dL (≥11.1 mmol/L) iii)Fasting plasma glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Prediabetes: 100–125 mg/dL (5.6–6.9 mmol/L) Diabetes: ≥126 mg/dL (≥7.0 mmol/L) iv)Random glucose value with classic</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL (≥11.1 mmol/L) • There is insufficient evidence </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'• In the absence of unequivocal hyperglycemia (e.g., hyperglycemic crisis), diagnosis of type 2 diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">requires confirmatory testing, which can be a different test on the same day or the same test on a different day. •</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Marked discordance between A1C and repeated blood (B) Classification Classification of diabetes type is not always </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">straightforward at presentation, and misdiagnosis is common. i)Type 1 diabetes (idiopathic or autoimmune β-cell </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">destruction) ii)Type 2 diabetes (non-autoimmune progressive loss of adequate β-cell insulin secretion frequently on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the background of insulin resistance and metabolic syndrome) iii)Gestational diabetes mellitus (GDM; detected at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">24–28 weeks of gestation in individuals without previously identified diabetes or high-risk glucose metabolism) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">iv)Diabetes from other causes (e.g., monogenic diabetes syndromes, diseases of the exocrine pancreas, and drug- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">chemical-induced diabetes) (C)Screening Criteria for Prediabetes and Type 2 Diabetes: Screening for prediabetes and</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 2 diabetes should be performed in asymptomatic adults with an informal assessment of risk factors or a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">validated risk calculator.'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'(D)Informal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i) Everyone ≥35 years of age ii)People </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with prior GDM iii)History of prediabetes iv)People with HIV, exposure to high-risk medicines, or a history of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pancreatitis. Adults (≥18 years of age) with overweight or obesity (BMI ≥25 kg/m2 or ≥23 kg/m2 in Asian American </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individuals) who have one or more of the following risk factors: ʜ First-degree relative with diabetes ʜ High-risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension (≥130/80 mmHg or on therapy for hypertension) ʜ </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Polycystic ovary syndrome ʜ HDL cholestorol &lt;35 mg/dL (&lt;0.9 mmol/L) and/or trigylcerides &gt;250 mg/dL (&gt;2.8 mmol/L) ʜ</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Physical inactivity ʜ Other clinical conditions associated with insulin resistance (E) Clinical Notes i) If results</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are normal, repeat screening at least every 3 years (annually for those with prediabetes), or sooner with symptoms </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">or changes in risk.'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'ii) Risk-based screening for prediabetes or type 2 diabetes should be considered after the onset of puberty or</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">after 10 years of age, whichever occurs earlier, in children and adolescents with overweight (BMI ≥85th percentile)</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">or obesity (BMI ≥95th percentile) who have one or more risk factors for diabetes. (F) i) (a) condition: An altered </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">relationship between A1C and glycemia (b) clinical tips: A mismatch between A1C and glycemia could be caused by </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">some hemoglobin variants, pregnancy (second and third trimesters and the postpartum period), glucose-6-phosphate </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">dehydrogenase deficiency, HIV, hemodialysis, recent blood loss or transfusion, anemia, or erythropoietin therapy. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">People with HIV should be screened for diabetes and prediabetes before and 3–6 months after starting or changing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">antiretroviral therapy and annually if initial results are normal. (c) best test:Fasting plasmaglucose ii) (a) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">condition: Acute pancreatitis (b) clinical tips: Screen for diabetes 3-6 months after an episode of acute </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pancreatitis and annually thereafter.'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'(c) best test: Any standard test for diagnosing diabetes iii) (a) condition: Cystic fibrosis (b) clinical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tips: Annual screening should begin by the age of 10 years in all people with cystic fibrosis not previously </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed with cystic fibrosis-related diabetes (c) best test: Oral glucose tolerance test iv) (a) condition: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Posttransplantation status (b) clinical tips: Screen for hyperglycemia after organ transplantation. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Posttransplantation diabetes mellitus should be diagnosed when the individual is stable on immunosuppressive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy and free of acute infections. (c) best test: Oral glucose tolerance test v) (a) condition: Possible </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monogenic diabetes (b) clinical tips: Suspect monogenic diabetes in people diagnosed with diabetes in the first 6 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">months of life and in children and young adults with atypical characteristics of type 1 or type 2 diabetes, who </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">often have a family history of diabetes in successive generations (suggestive of an autosomal dominant pattern of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inheritance).'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'(c) best test:Any standard test for diagnosing diabetes plus appropriate genetic testing vi) (a) condition: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Therapy with certain medications (b) clinical tips: Consider screening people for prediabetes or diabetes if they </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are on certain medications known to increase diabetes risk, such as glucocorticoids, statins, thiazide diuretics, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">some HIV medications, and second-generation antipsychotic medications. (c) best test:Any standard test test for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosing diabetes'</span>\n",
              "<span style=\"font-weight: bold\">]</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#helper function to capture the lengths of each split\n",
        "\n",
        "def get_split_lengths(splits: List[List[str]], column_name: str='Split Lengths') -> pd.DataFrame:\n",
        "    '''\n",
        "    Given a list of text splits, returns the length of each split\n",
        "    in a pandas DataFrame.\n",
        "    '''\n",
        "    lengths = list(map(len, splits))\n",
        "    return pd.DataFrame(lengths, columns=[column_name])"
      ],
      "metadata": {
        "id": "ny70umHJa3TY"
      },
      "execution_count": 13,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import matplotlib.ticker as ticker\n",
        "\n",
        "column_name = 'Split Lengths'\n",
        "\n",
        "# replace None with the output from the split_contents function\n",
        "df = get_split_lengths(content_splits , column_name=column_name)\n",
        "df['Split Lengths'] = df['Split Lengths'] * chunk_size\n",
        "\n",
        "# reverse the order of the episode # to correctly show left to right chronological order\n",
        "df.index = sorted(list(df.index), reverse=True)\n",
        "# create plot\n",
        "ax = df.iloc[::-1].plot.bar(y='Split Lengths', xlabel='Papers #', ylabel='Approx. Length in Tokens', title='Paper Length (in tokens) over Time', figsize=(20,8))\n",
        "ax.xaxis.set_major_locator(ticker.MultipleLocator(1))"
      ],
      "metadata": {
        "collapsed": true,
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 722
        },
        "id": "1erANCxRa44T",
        "outputId": "e27677d5-2002-4f8c-d216-76b1383d11c0"
      },
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 2000x800 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def join_metadata(data: list[dict], content_splits: list[list[str]]) -> list[dict]:\n",
        "\n",
        "    joined_documents = []\n",
        "\n",
        "    for i, episode in enumerate(data):\n",
        "        for j, text in enumerate(content_splits[i]):\n",
        "            new_doc = {}\n",
        "            new_doc['doc_id'] = data[i]['doc_id']\n",
        "            new_doc[\"content_id\"] = data[i]['doc_id'] + \"_cont_\" + str(j+1)\n",
        "            new_doc['doc_name'] = data[i]['doc_name']\n",
        "            new_doc[\"summary\"] = data[i]['Summary']\n",
        "            new_doc[\"content\"] = text\n",
        "            joined_documents.append(new_doc)\n",
        "\n",
        "    return joined_documents"
      ],
      "metadata": {
        "collapsed": true,
        "id": "IrAjZjAha6h6"
      },
      "execution_count": 15,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "docs = join_metadata(data, content_splits )\n",
        "print(docs[:5])"
      ],
      "metadata": {
        "collapsed": true,
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "Cu7LGJxUgpTK",
        "outputId": "b1a0d37e-118e-4856-84f5-b656e0f8eebe"
      },
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1m[\u001b[0m\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_1'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_1_cont_1'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic Tests for Diabetes: i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mA1C Prediabetes: \u001b[0m\n",
              "\u001b[32m5.7–6.4% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m39–47 mmol/ mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥6.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥48 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 2-hour glucose value during a 75-g oral glucose \u001b[0m\n",
              "\u001b[32mtolerance test Prediabetes: 140–199 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m7.8–11.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mFasting plasma \u001b[0m\n",
              "\u001b[32mglucose Prediabetes: 100–125 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.6–6.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥126 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥7.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mRandom glucose value with\u001b[0m\n",
              "\u001b[32mclassic hyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • There is insufficient \u001b[0m\n",
              "\u001b[32mevidence to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_1'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_1_cont_2'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'• In the absence of unequivocal hyperglycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hyperglycemic crisis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, diagnosis of type 2\u001b[0m\n",
              "\u001b[32mdiabetes requires confirmatory testing, which can be a different test on the same day or the same test on a \u001b[0m\n",
              "\u001b[32mdifferent day. • Marked discordance between A1C and repeated blood \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Classification Classification of diabetes \u001b[0m\n",
              "\u001b[32mtype is not always straightforward at presentation, and misdiagnosis is common. i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 1 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32midiopathic or \u001b[0m\n",
              "\u001b[32mautoimmune β-cell destruction\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 2 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mnon-autoimmune progressive loss of adequate β-cell insulin \u001b[0m\n",
              "\u001b[32msecretion frequently on the background of insulin resistance and metabolic syndrome\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mGestational diabetes \u001b[0m\n",
              "\u001b[32mmellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM; detected at 24–28 weeks of gestation in individuals without previously identified diabetes or \u001b[0m\n",
              "\u001b[32mhigh-risk glucose metabolism\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mDiabetes from other causes \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., monogenic diabetes syndromes, diseases of the \u001b[0m\n",
              "\u001b[32mexocrine pancreas, and drug- or chemical-induced diabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32mScreening Criteria for Prediabetes and Type 2 \u001b[0m\n",
              "\u001b[32mDiabetes: Screening for prediabetes and type 2 diabetes should be performed in asymptomatic adults with an informal\u001b[0m\n",
              "\u001b[32massessment of risk factors or a validated risk calculator.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_1'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_1_cont_3'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32mInformal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Everyone ≥35 years of\u001b[0m\n",
              "\u001b[32mage ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with prior GDM iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mHistory of prediabetes iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with HIV, exposure to high-risk medicines, or a \u001b[0m\n",
              "\u001b[32mhistory of pancreatitis. Adults \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥18 years of age\u001b[0m\u001b[32m)\u001b[0m\u001b[32m with overweight or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥25 kg/m2 or ≥23 kg/m2 in Asian \u001b[0m\n",
              "\u001b[32mAmerican individuals\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more of the following risk factors: ʜ First-degree relative with diabetes ʜ \u001b[0m\n",
              "\u001b[32mHigh-risk race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥130/80 mmHg or on therapy for \u001b[0m\n",
              "\u001b[32mhypertension\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ Polycystic ovary syndrome ʜ HDL cholestorol \u001b[0m\u001b[32m<\u001b[0m\u001b[32m35\u001b[0m\u001b[32m mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<0.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and/or trigylcerides >250 mg/dL\u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m>\u001b[0m\u001b[32m2.8 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ Physical inactivity ʜ Other clinical conditions associated with insulin resistance \u001b[0m\u001b[32m(\u001b[0m\u001b[32mE\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Clinical \u001b[0m\n",
              "\u001b[32mNotes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m If results are normal, repeat screening at least every 3 years \u001b[0m\u001b[32m(\u001b[0m\u001b[32mannually for those with prediabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, or \u001b[0m\n",
              "\u001b[32msooner with symptoms or changes in risk.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_1'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_1_cont_4'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Risk-based screening for prediabetes or type 2 diabetes should be considered after the \u001b[0m\n",
              "\u001b[32monset of puberty or after 10 years of age, whichever occurs earlier, in children and adolescents with overweight \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mBMI ≥85th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥95th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more risk factors for diabetes. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mF\u001b[0m\u001b[32m)\u001b[0m\u001b[32m i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\n",
              "\u001b[32mcondition: An altered relationship between A1C and glycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: A mismatch between A1C and glycemia \u001b[0m\n",
              "\u001b[32mcould be caused by some hemoglobin variants, pregnancy \u001b[0m\u001b[32m(\u001b[0m\u001b[32msecond and third trimesters and the postpartum period\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, \u001b[0m\n",
              "\u001b[32mglucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss or transfusion, anemia, or \u001b[0m\n",
              "\u001b[32merythropoietin therapy. People with HIV should be screened for diabetes and prediabetes before and 3–6 months after\u001b[0m\n",
              "\u001b[32mstarting or changing antiretroviral therapy and annually if initial results are normal. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Fasting \u001b[0m\n",
              "\u001b[32mplasmaglucose ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Acute pancreatitis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for diabetes 3-6 months after an \u001b[0m\n",
              "\u001b[32mepisode of acute pancreatitis and annually thereafter.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_1'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_1_cont_5'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Any standard test for diagnosing diabetes iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Cystic fibrosis \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Annual screening should begin by the age of 10 years in all people with cystic fibrosis not \u001b[0m\n",
              "\u001b[32mpreviously diagnosed with cystic fibrosis-related diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mcondition: Posttransplantation status \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for hyperglycemia after organ transplantation. \u001b[0m\n",
              "\u001b[32mPosttransplantation diabetes mellitus should be diagnosed when the individual is stable on immunosuppressive \u001b[0m\n",
              "\u001b[32mtherapy and free of acute infections. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test v\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Possible \u001b[0m\n",
              "\u001b[32mmonogenic diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Suspect monogenic diabetes in people diagnosed with diabetes in the first 6 \u001b[0m\n",
              "\u001b[32mmonths of life and in children and young adults with atypical characteristics of type 1 or type 2 diabetes, who \u001b[0m\n",
              "\u001b[32moften have a family history of diabetes in successive generations \u001b[0m\u001b[32m(\u001b[0m\u001b[32msuggestive of an autosomal dominant pattern of \u001b[0m\n",
              "\u001b[32minheritance\u001b[0m\u001b[32m)\u001b[0m\u001b[32m.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m\n",
              "\u001b[1m]\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"font-weight: bold\">[</span>\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes (A) Diagnostic Tests for Diabetes: i)A1C Prediabetes: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">5.7–6.4% (39–47 mmol/ mol) Diabetes: ≥6.5% (≥48 mmol/mol) ii) 2-hour glucose value during a 75-g oral glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tolerance test Prediabetes: 140–199 mg/dL (7.8–11.0 mmol/L) Diabetes: ≥200 mg/dL (≥11.1 mmol/L) iii)Fasting plasma </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose Prediabetes: 100–125 mg/dL (5.6–6.9 mmol/L) Diabetes: ≥126 mg/dL (≥7.0 mmol/L) iv)Random glucose value with</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">classic hyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL (≥11.1 mmol/L) • There is insufficient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">evidence to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_2'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'• In the absence of unequivocal hyperglycemia (e.g., hyperglycemic crisis), diagnosis of type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes requires confirmatory testing, which can be a different test on the same day or the same test on a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">different day. • Marked discordance between A1C and repeated blood (B) Classification Classification of diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type is not always straightforward at presentation, and misdiagnosis is common. i)Type 1 diabetes (idiopathic or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">autoimmune β-cell destruction) ii)Type 2 diabetes (non-autoimmune progressive loss of adequate β-cell insulin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">secretion frequently on the background of insulin resistance and metabolic syndrome) iii)Gestational diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mellitus (GDM; detected at 24–28 weeks of gestation in individuals without previously identified diabetes or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">high-risk glucose metabolism) iv)Diabetes from other causes (e.g., monogenic diabetes syndromes, diseases of the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">exocrine pancreas, and drug- or chemical-induced diabetes) (C)Screening Criteria for Prediabetes and Type 2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Diabetes: Screening for prediabetes and type 2 diabetes should be performed in asymptomatic adults with an informal</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment of risk factors or a validated risk calculator.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_3'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'(D)Informal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i) Everyone ≥35 years of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">age ii)People with prior GDM iii)History of prediabetes iv)People with HIV, exposure to high-risk medicines, or a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">history of pancreatitis. Adults (≥18 years of age) with overweight or obesity (BMI ≥25 kg/m2 or ≥23 kg/m2 in Asian </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">American individuals) who have one or more of the following risk factors: ʜ First-degree relative with diabetes ʜ </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">High-risk race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension (≥130/80 mmHg or on therapy for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hypertension) ʜ Polycystic ovary syndrome ʜ HDL cholestorol &lt;35 mg/dL (&lt;0.9 mmol/L) and/or trigylcerides &gt;250 mg/dL</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(&gt;2.8 mmol/L) ʜ Physical inactivity ʜ Other clinical conditions associated with insulin resistance (E) Clinical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Notes i) If results are normal, repeat screening at least every 3 years (annually for those with prediabetes), or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">sooner with symptoms or changes in risk.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_4'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'ii) Risk-based screening for prediabetes or type 2 diabetes should be considered after the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">onset of puberty or after 10 years of age, whichever occurs earlier, in children and adolescents with overweight </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(BMI ≥85th percentile) or obesity (BMI ≥95th percentile) who have one or more risk factors for diabetes. (F) i) (a)</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">condition: An altered relationship between A1C and glycemia (b) clinical tips: A mismatch between A1C and glycemia </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">could be caused by some hemoglobin variants, pregnancy (second and third trimesters and the postpartum period), </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss or transfusion, anemia, or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">erythropoietin therapy. People with HIV should be screened for diabetes and prediabetes before and 3–6 months after</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">starting or changing antiretroviral therapy and annually if initial results are normal. (c) best test:Fasting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plasmaglucose ii) (a) condition: Acute pancreatitis (b) clinical tips: Screen for diabetes 3-6 months after an </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">episode of acute pancreatitis and annually thereafter.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_5'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'(c) best test: Any standard test for diagnosing diabetes iii) (a) condition: Cystic fibrosis </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(b) clinical tips: Annual screening should begin by the age of 10 years in all people with cystic fibrosis not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">previously diagnosed with cystic fibrosis-related diabetes (c) best test: Oral glucose tolerance test iv) (a) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">condition: Posttransplantation status (b) clinical tips: Screen for hyperglycemia after organ transplantation. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Posttransplantation diabetes mellitus should be diagnosed when the individual is stable on immunosuppressive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy and free of acute infections. (c) best test: Oral glucose tolerance test v) (a) condition: Possible </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monogenic diabetes (b) clinical tips: Suspect monogenic diabetes in people diagnosed with diabetes in the first 6 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">months of life and in children and young adults with atypical characteristics of type 1 or type 2 diabetes, who </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">often have a family history of diabetes in successive generations (suggestive of an autosomal dominant pattern of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inheritance).'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>\n",
              "<span style=\"font-weight: bold\">]</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(len(docs))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 33
        },
        "id": "PegnTeqx1ryR",
        "outputId": "d75f995c-57b4-4c0f-af9a-6bf0910866b3"
      },
      "execution_count": 18,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1;36m91\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">91</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "\n",
        "with open('Split_Data_Med.json', 'w') as f:\n",
        "    json.dump(docs, f, indent=4)"
      ],
      "metadata": {
        "id": "nedPj5KL1UvY"
      },
      "execution_count": 21,
      "outputs": []
    }
  ]
}